Crescita Therapeutics (TSE:CTX) Reaches New 52-Week High – Should You Buy?

Crescita Therapeutics Inc. (TSE:CTX)’s share price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as C$0.75 and last traded at C$0.75, with a volume of 20100 shares traded. The stock had previously closed at C$0.74.

Crescita Therapeutics Trading Up 1.4%

The company has a debt-to-equity ratio of 2.98, a quick ratio of 2.29 and a current ratio of 3.12. The business has a fifty day simple moving average of C$0.56 and a 200 day simple moving average of C$0.50. The stock has a market cap of C$13.96 million, a price-to-earnings ratio of 37.50 and a beta of -1.55.

Crescita Therapeutics (TSE:CTX) last released its quarterly earnings results on Tuesday, March 31st. The company reported C($0.04) earnings per share for the quarter. The company had revenue of C$5.96 million during the quarter. Crescita Therapeutics had a return on equity of 2.92% and a net margin of 2.07%.

About Crescita Therapeutics

Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The firm generates its revenue in the form of product sales and out-licensing revenue.